Cargando…

Treatment of Drug Susceptible Pulmonary Tuberculosis

Tuberculosis (TB) remains a major global health problem, and the incidence of TB cases has not significantly decreased over the past decade in Korea. The standard short course regimen is highly effective against TB, but requires multiple TB-specific drugs and a long treatment duration. Recent studie...

Descripción completa

Detalles Bibliográficos
Autores principales: Shin, Hong-Joon, Kwon, Yong-Soo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Academy of Tuberculosis and Respiratory Diseases 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4499581/
https://www.ncbi.nlm.nih.gov/pubmed/26175767
http://dx.doi.org/10.4046/trd.2015.78.3.161
_version_ 1782380806589644800
author Shin, Hong-Joon
Kwon, Yong-Soo
author_facet Shin, Hong-Joon
Kwon, Yong-Soo
author_sort Shin, Hong-Joon
collection PubMed
description Tuberculosis (TB) remains a major global health problem, and the incidence of TB cases has not significantly decreased over the past decade in Korea. The standard short course regimen is highly effective against TB, but requires multiple TB-specific drugs and a long treatment duration. Recent studies using late-generation fluoroquinolones and/or high-dose rifapentine-containing regimens to shorten the duration of TB treatment showed negative results. Extending the treatment duration may be considered in patients with cavitation on the initial chest radiograph and positivity in sputum culture at 2 months of treatment for preventing TB relapse. Current evidence does not support the use of fixed-dose combinations compared to separate drugs for the purpose of improving treatment outcomes. All patients receiving TB treatment should be monitored regularly for response to therapy, facilitation of treatment completion, and management of adverse drug reactions. Mild adverse effects can be managed with symptomatic therapy and changing the timing of the drug administration, but severe adverse effects require a discontinuation of the offending drugs.
format Online
Article
Text
id pubmed-4499581
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher The Korean Academy of Tuberculosis and Respiratory Diseases
record_format MEDLINE/PubMed
spelling pubmed-44995812015-07-14 Treatment of Drug Susceptible Pulmonary Tuberculosis Shin, Hong-Joon Kwon, Yong-Soo Tuberc Respir Dis (Seoul) Review Tuberculosis (TB) remains a major global health problem, and the incidence of TB cases has not significantly decreased over the past decade in Korea. The standard short course regimen is highly effective against TB, but requires multiple TB-specific drugs and a long treatment duration. Recent studies using late-generation fluoroquinolones and/or high-dose rifapentine-containing regimens to shorten the duration of TB treatment showed negative results. Extending the treatment duration may be considered in patients with cavitation on the initial chest radiograph and positivity in sputum culture at 2 months of treatment for preventing TB relapse. Current evidence does not support the use of fixed-dose combinations compared to separate drugs for the purpose of improving treatment outcomes. All patients receiving TB treatment should be monitored regularly for response to therapy, facilitation of treatment completion, and management of adverse drug reactions. Mild adverse effects can be managed with symptomatic therapy and changing the timing of the drug administration, but severe adverse effects require a discontinuation of the offending drugs. The Korean Academy of Tuberculosis and Respiratory Diseases 2015-07 2015-06-30 /pmc/articles/PMC4499581/ /pubmed/26175767 http://dx.doi.org/10.4046/trd.2015.78.3.161 Text en Copyright©2015. The Korean Academy of Tuberculosis and Respiratory Diseases. All rights reserved. http://creativecommons.org/licenses/by-nc/4.0/ It is identical to the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/)
spellingShingle Review
Shin, Hong-Joon
Kwon, Yong-Soo
Treatment of Drug Susceptible Pulmonary Tuberculosis
title Treatment of Drug Susceptible Pulmonary Tuberculosis
title_full Treatment of Drug Susceptible Pulmonary Tuberculosis
title_fullStr Treatment of Drug Susceptible Pulmonary Tuberculosis
title_full_unstemmed Treatment of Drug Susceptible Pulmonary Tuberculosis
title_short Treatment of Drug Susceptible Pulmonary Tuberculosis
title_sort treatment of drug susceptible pulmonary tuberculosis
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4499581/
https://www.ncbi.nlm.nih.gov/pubmed/26175767
http://dx.doi.org/10.4046/trd.2015.78.3.161
work_keys_str_mv AT shinhongjoon treatmentofdrugsusceptiblepulmonarytuberculosis
AT kwonyongsoo treatmentofdrugsusceptiblepulmonarytuberculosis